Literature DB >> 31137064

Lung Diseases in Inflammatory Myopathies.

Thomas Barba1, Sabine Mainbourg2, Mouhamad Nasser3, Jean-Christophe Lega2, Vincent Cottin3.   

Abstract

Lung involvement is the leading cause of mortality in inflammatory myopathy. A careful assessment of clinical and serologic manifestations especially myositis-associated autoantibodies allows precise classification of the different phenotypes of inflammatory myopathy and stratification of the risk of lung involvement. About three out of four patients with inflammatory myopathy develop interstitial lung disease (ILD), which represents the main cause of morbidity and mortality. In patients with a confirmed diagnosis of inflammatory myopathy, the approach to the diagnosis of ILD includes assessment of clinical and functional severity, evaluation of the high-resolution computed tomography pattern of disease, which often suggests nonspecific interstitial pneumonia or organizing pneumonia. Bronchoalveolar lavage to rule out infection is often performed; however, video-assisted thoracoscopic lung biopsy is now generally discouraged, unless malignancy is suspected. The so-called antisynthetase syndrome characterized by the combination of mechanics' hands, Raynaud' phenomenon, myositis often mild or absent, and presence of one of the anti-tRNA synthetase antibodies is associated with a 70% risk of ILD, especially in subjects with antibodies other than anti-Jo1 antibodies (i.e., anti-PL7 or -PL12 antibodies). Treatment depends on both severity and progression of ILD, often including a combination of corticosteroids and immunosuppressive therapy. Rituximab-based regimen has showed promising results in retrospective studies for the management of refractory or rapidly progressive forms of ILD. Clinical trials are ongoing to evaluate the actual efficacy of this strategy on mortality related to lung disease. Secondary pulmonary complications of inflammatory myopathy include opportunistic infections, aspiration pneumonia, pneumomediastinum, ventilatory failure due to diaphragmatic muscular weakness, drug-induced pneumonitis, and rarely pulmonary hypertension. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31137064     DOI: 10.1055/s-0039-1685187

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  5 in total

1.  [Clinical and immunological characteristics of 88 cases of overlap myositis].

Authors:  Y S Xiao; F Y Zhu; L Luo; X Y Xing; Y H Li; X W Zhang; D H Shen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

2.  The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease.

Authors:  Wen-Chih Lin; Po-Yu Lin; Hung-Ling Huang; Meng-Yu Weng; Yuan-Ting Sun
Journal:  Neurol Sci       Date:  2020-11-19       Impact factor: 3.307

Review 3.  PET Scan: Nuclear Medicine Imaging in Myositis.

Authors:  Albert Selva-O'Callaghan; Albert Gil-Vila; Marc Simó-Perdigó; Ernesto Trallero-Araguás; Marcelo Alvarado-Cárdenas; Iago Pinal-Fernandez
Journal:  Curr Rheumatol Rep       Date:  2019-11-21       Impact factor: 4.592

4.  Characterisation of Disease Patterns of Dermatomyositis with Different Initial Manifestations.

Authors:  Yue Sun; Dai-Feng Li; Yin-Li Zhang; Xu Liang; Tian-Fang Li
Journal:  Int J Gen Med       Date:  2022-08-09

5.  [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].

Authors:  Katharina Buschulte; Anna-Maria Hoffmann-Vold; Rucsan Dra Dobrota; Philipp Höger; Andreas Krause; Michael Kreuter
Journal:  Z Rheumatol       Date:  2021-09-10       Impact factor: 1.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.